Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0054 USD
Change Today +0.0006 / 12.50%
Volume 566.3K
TSOI On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

therapeutic solutions intern (TSOI) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/9/15 - $0.02
52 Week Low
03/30/15 - $0.0011
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

therapeutic solutions intern (TSOI) Related Businessweek News

No Related Businessweek News Found

therapeutic solutions intern (TSOI) Details

Therapeutic Solutions International, Inc. manufactures and sells plastic intraoral devices in the United States and internationally. The company offers Anterior Midpoint Stop Appliances (AMPSA), which are used for the treatment and prevention of common neurological and temporomandibular disorders, including migraine headaches, migraine pain, and bruxism. Therapeutic Solutions International, Inc. sells its products under the AMPSA CS and Migran-X names, as well as under the NTI and NTI-tss names directly to licensed dentists in the United States, as well as to licensed dentists internationally directly and through distributors. It also provides AMPSA-related educational programs. Therapeutic Solutions International, Inc. is based in Oceanside, California.

therapeutic solutions intern (TSOI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

therapeutic solutions intern (TSOI) Key Developments

Therapeutic Solutions International, Inc. Expands Immunotherapy Based Product Pipeline by Filing New Patent Application

Therapeutic Solutions International, Inc. announced the filing of a patent application covering a proprietary probiotic mixture which reduced immunologically mediated spontaneous abortions in an established animal model of recurrent first trimester miscarriages. TSOI collaborators bred male DBA mice with female CBA mice, a mating combination that is known to result in high levels of fetal loss caused by maternal immune attack on the fetus1. Ten mother mice were orally administered placebo control daily, and ten received the proprietary probiotic mixture daily. Mothers that had received placebo had an average of 3 live offspring with 5 fetuses destroyed by the maternal immune system. In contrast, mothers that received the probiotic mixture had an average of 7 live offspring and 1 immunologically destroyed fetus. The incidence of recurrent miscarriages in women of reproductive age seeking pregnancies is reported to be 1-2%. Patients presenting with recurrent miscarriages have experienced psychological trauma as they face the uncertainty of the outcome of the next pregnancy, and a variety of psychological and psychiatric disorders including anxiety, depression, posttraumatic stress disorders, and obsessive-compulsive disorders develop in these patients after miscarriages.

United States Patent and Trademark Office Accepts U.S. Application No. 62/190170 for ProJuvenol of Therapeutics Solutions International, Inc

Therapeutics Solutions International, Inc. announced the filing of a patent application covering the use of its ProJuvenol product, as well as various pterostilbene compositions, for use in augmenting efficacy of existing immuno-oncology drugs that are currently on the market. The patent is based on the ability of pterostilbene, one of the major ingredients of ProJuvenol, to reduce oxidative stress produced by cancer cells, which in turn protects the immune system from cancer mediated immune suppression. On July 8, 2015, the United States Patent and Trademark Office accepted U.S. Application No. 62/190170 titled Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions.

Therapeutic Solutions International, Inc. announced delayed annual 10-K filing

On 03/31/2014, Therapeutic Solutions International, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TSOI:US $0.01 USD +0.0006

TSOI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TSOI.
View Industry Companies

Industry Analysis


Industry Average

Valuation TSOI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAPEUTIC SOLUTIONS INTERN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at